KR20210050033A - A composition for improving, preventing and treating of gastrointestinal disease - Google Patents
A composition for improving, preventing and treating of gastrointestinal disease Download PDFInfo
- Publication number
- KR20210050033A KR20210050033A KR1020190133633A KR20190133633A KR20210050033A KR 20210050033 A KR20210050033 A KR 20210050033A KR 1020190133633 A KR1020190133633 A KR 1020190133633A KR 20190133633 A KR20190133633 A KR 20190133633A KR 20210050033 A KR20210050033 A KR 20210050033A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- thistle
- helicobacter pylori
- mixed
- gastric
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 128
- 208000018522 Gastrointestinal disease Diseases 0.000 title description 2
- 208000010643 digestive system disease Diseases 0.000 title description 2
- 208000018685 gastrointestinal system disease Diseases 0.000 title 1
- 239000000284 extract Substances 0.000 claims abstract description 141
- 240000007124 Brassica oleracea Species 0.000 claims abstract description 67
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 67
- 235000008397 ginger Nutrition 0.000 claims abstract description 67
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims abstract description 61
- 241000590002 Helicobacter pylori Species 0.000 claims abstract description 53
- 235000012907 honey Nutrition 0.000 claims abstract description 50
- 229940037467 helicobacter pylori Drugs 0.000 claims abstract description 48
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 claims abstract description 46
- 208000018556 stomach disease Diseases 0.000 claims abstract description 45
- 235000013305 food Nutrition 0.000 claims abstract description 29
- 239000004480 active ingredient Substances 0.000 claims abstract description 20
- 230000002265 prevention Effects 0.000 claims abstract description 10
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 claims description 66
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 claims description 66
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 claims description 66
- 241000234314 Zingiber Species 0.000 claims description 66
- 241000132536 Cirsium Species 0.000 claims description 56
- 241000245665 Taraxacum Species 0.000 claims description 29
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims description 29
- 238000002156 mixing Methods 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 208000007882 Gastritis Diseases 0.000 claims description 11
- 241000544066 Stevia Species 0.000 claims description 10
- 230000006872 improvement Effects 0.000 claims description 8
- 208000012895 Gastric disease Diseases 0.000 claims description 6
- 208000023652 chronic gastritis Diseases 0.000 claims description 6
- 206010025323 Lymphomas Diseases 0.000 claims description 5
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 5
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 5
- 208000000718 duodenal ulcer Diseases 0.000 claims description 5
- 206010017758 gastric cancer Diseases 0.000 claims description 5
- 201000011587 gastric lymphoma Diseases 0.000 claims description 5
- 201000005917 gastric ulcer Diseases 0.000 claims description 5
- 201000011549 stomach cancer Diseases 0.000 claims description 5
- 241000894006 Bacteria Species 0.000 claims description 4
- 244000228451 Stevia rebaudiana Species 0.000 abstract description 36
- 230000000694 effects Effects 0.000 abstract description 25
- 238000011282 treatment Methods 0.000 abstract description 17
- 235000005911 diet Nutrition 0.000 abstract description 3
- 230000037213 diet Effects 0.000 abstract description 3
- 241000729173 Cirsium japonicum Species 0.000 abstract description 2
- 241000691199 Taraxacum platycarpum Species 0.000 abstract description 2
- 231100000252 nontoxic Toxicity 0.000 abstract description 2
- 230000003000 nontoxic effect Effects 0.000 abstract description 2
- 235000011303 Brassica alboglabra Nutrition 0.000 abstract 1
- 235000011302 Brassica oleracea Nutrition 0.000 abstract 1
- 244000273928 Zingiber officinale Species 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 239000001841 zingiber officinale Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- 239000000843 powder Substances 0.000 description 20
- 238000000605 extraction Methods 0.000 description 17
- 238000009472 formulation Methods 0.000 description 14
- 230000036541 health Effects 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- 241000589989 Helicobacter Species 0.000 description 12
- 239000004615 ingredient Substances 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 11
- 239000008187 granular material Substances 0.000 description 11
- 239000002904 solvent Substances 0.000 description 10
- 239000003826 tablet Substances 0.000 description 10
- 239000002775 capsule Substances 0.000 description 9
- 235000013376 functional food Nutrition 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 229920001817 Agar Polymers 0.000 description 7
- 239000008272 agar Substances 0.000 description 7
- 235000010419 agar Nutrition 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 235000013355 food flavoring agent Nutrition 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 235000013361 beverage Nutrition 0.000 description 5
- 235000019658 bitter taste Nutrition 0.000 description 5
- 235000003599 food sweetener Nutrition 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 239000003765 sweetening agent Substances 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 235000008504 concentrate Nutrition 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- -1 flavonoid compound Chemical class 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 235000010841 Silybum marianum Nutrition 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000012669 liquid formulation Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 244000272459 Silybum marianum Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 235000015218 chewing gum Nutrition 0.000 description 2
- 229940112822 chewing gum Drugs 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000008029 eradication Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000020510 functional beverage Nutrition 0.000 description 2
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 2
- 235000001727 glucose Nutrition 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 235000019204 saccharin Nutrition 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 229940081974 saccharin Drugs 0.000 description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 2
- 229960004245 silymarin Drugs 0.000 description 2
- 235000017700 silymarin Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- ZPSJGADGUYYRKE-UHFFFAOYSA-N 2H-pyran-2-one Chemical compound O=C1C=CC=CO1 ZPSJGADGUYYRKE-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241001573881 Corolla Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 208000014540 Functional gastrointestinal disease Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019375 Helicobacter infections Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 241001310492 Pectis angustifolia Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 241000320380 Silybum Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 235000006092 Stevia rebaudiana Nutrition 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 241001464837 Viridiplantae Species 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000002686 anti-diuretic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000002956 ash Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000002888 effect on disease Effects 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 235000015206 pear juice Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 235000019654 spicy taste Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L21/00—Marmalades, jams, jellies or the like; Products from apiculture; Preparation or treatment thereof
- A23L21/20—Products from apiculture, e.g. royal jelly or pollen; Substitutes therefor
- A23L21/25—Honey; Honey substitutes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/30—Artificial sweetening agents
- A23L27/33—Artificial sweetening agents containing sugars or derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Insects & Arthropods (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 엉겅퀴, 민들레, 양배추, 꿀 및 생강으로 이루어진 혼합물을 함유하는 헬리코박터 파이로리균에 의해 발생하는 위질환의 예방, 치료 또는 개선용 조성물에 관한 것이다.The present invention relates to a composition for preventing, treating or improving gastric diseases caused by Helicobacter pylori containing a mixture consisting of thistle, dandelion, cabbage, honey and ginger.
소화기질환에는 간염, 간경화 등 간 관련 질환과 대장염, 대장암, 위장염, 위암, 기능성위장장애, 장염 등 위와 장 관련 질환 등이 있으며, 세균, 스트레스, 알코올, 식생활, 노령화, 유전적 등 다양한 원인이 되어 줄어들지 않고 있는 실정이다. Digestive diseases include liver-related diseases such as hepatitis and cirrhosis, and stomach and intestinal diseases such as colitis, colon cancer, gastroenteritis, gastric cancer, functional gastrointestinal disorder, and enteritis. The situation is not decreasing.
특히, 위질환의 원인으로 헬리코박터 파이로니 등 세균질환에 의한 요인, 스트레스 등에 물리적에 의한 요인, 에탄올 등 화학적에 의한 요인과 같이 세부적으로 크게 구분할 수 있다.Particularly, the causes of gastric diseases can be classified largely as factors due to bacterial diseases such as Helicobacter pyrone, physical factors such as stress, and chemical factors such as ethanol.
상기 헬리코박터균은 위장 점막에 주로 감염되어 급성 위염, 만성 위염, 위궤양, 십이지장궤양, 위림프종의 직접적인 원인이 되며, 헬리코박터균에 의한 만성 위염이 지속되면 위장 점막에 위축성 변화가 발생하고, 이후 여러 가지 환경적 요인과 유전적 요인이 작용하여 위선암의 발생률이 높아진다고 알려져 있다. 따라서, 헬리코박터균은 1994년 세계보건기구(WHO)에서 1급암 유발 인자로 경고된 바 있다.The Helicobacter bacteria are mainly infected in the gastrointestinal mucosa and are a direct cause of acute gastritis, chronic gastritis, gastric ulcer, duodenal ulcer, and gastric lymphoma.If chronic gastritis caused by Helicobacter bacteria continues, an atrophic change occurs in the gastrointestinal mucosa. Environmental and genetic factors are known to increase the incidence of gastric adenocarcinoma. Therefore, Helicobacter bacteria were warned by the World Health Organization (WHO) as a first-degree cancer-causing factor in 1994.
우리나라 국민들에게서 헬리코박터균 감염은 무척 흔해서, 전 국민의 46.6%와 성인에서 69.4%의 감염률을 보이고 있다. 이러한 높은 헬리코박터균의 보균 비율은 우리나라 국민의 높은 위선암 발생률의 원인이 된다고 추측되고 있다. 헬리코박터균의 치료는 항생제를 이용하며, 일반적으로 이용하는 헬리코박터 1차 치료제는 항생제 2종류와 위산 억제재 한 종류를 포함해서 총 세 종류의 약으로 구성되어 있다. 이를 7~14일 복용하면 70~80% 정도의 확률로 헬리코박터균이 치료된다. 하지만 최근 헬리코박터균의 항생제 내성이 높아져 치료를 받아도 균이 없어지지 않는 경우가 점차 많아 문제가 되고 있고, 어떤 환자에게서 제균을 해야만 하는가에 대한 권고지침이 명확치 않다는 점 등의 이유에서 약물에 의한 제균치료 이외에 식품이나 천연물 추출물 등의 개발에 관심이 증가되고 있다. 특히, 2007년 Maastricht III consensus보고에 의하면 프로바이오틱스가 헬리코박터균 감염을 치료하기 위한 한 가지 도구가 될 수도 있음이 언급된 바 있다. Helicobacter infection is very common among Korean people, and the infection rate is 46.6% of the total population and 69.4% of adults. It is estimated that such a high carrier ratio of Helicobacter bacteria is the cause of the high incidence of gastric adenocarcinoma in the Korean people. Antibiotics are used to treat Helicobacter bacteria, and the commonly used first-line treatment for Helicobacter is composed of three types of drugs, including two antibiotics and one type of gastric acid inhibitor. If you take this for 7-14 days, Helicobacter bacteria are cured with a 70-80% probability. However, due to the recent increase in antibiotic resistance of Helicobacter bacteria, there are many cases in which the bacteria do not disappear even after treatment, which is a problem, and the recommended guidelines on which patients should be sterilized are not clear. In addition, there is increasing interest in the development of food or natural product extracts. In particular, according to the 2007 Maastricht III consensus report, it was mentioned that probiotics may be a tool for treating H. pylori infection.
또한 항생제를 이용한 헬리코박터균의 1차 제균 치료 시 유산균을 병용투여하면 제균율을 향상시키고 제균 치료제 사용으로 인한 합병증을 감소시킬 수 있음이 보고되었다[Sun Hee Roh. 2011. The Effect of Probiotics for Helicobacter pylori. The Korean Journal of Helicobacter and Upper Gastrointestinal Research. 11(1); 26-36].In addition, it has been reported that co-administration of lactic acid bacteria during the first antibacterial treatment of Helicobacter bacteria using antibiotics can improve the eradication rate and reduce complications caused by the use of an eradication treatment [Sun Hee Roh. 2011. The Effect of Probiotics for Helicobacter pylori. The Korean Journal of Helicobacter and Upper Gastrointestinal Research. 11(1); 26-36].
헬리코박터 파이로리균에 의해 발생하는 위질환을 지속적으로 치료를 수행하기 위해서는 화학적 약물보다는 부작용이 적으면서 안정성이 확보된 천연물을 이용한 치료제가 요구되고 있다.In order to continuously treat gastric diseases caused by Helicobacter pylori, there is a need for a therapeutic agent using natural products that have less side effects than chemical drugs and have secured stability.
본 발명의 목적은 엉겅퀴, 민들레, 양배추, 꿀 및 생강으로 이루어진 혼합물을 함유하여 헬리코박터 파이로리균에 의해 발생하는 위질환을 예방 또는 개선할 수 있는 식품 조성물을 제공하는데 있다.An object of the present invention is to provide a food composition capable of preventing or improving gastric diseases caused by Helicobacter pylori bacteria by containing a mixture consisting of thistle, dandelion, cabbage, honey and ginger.
또한, 본 발명의 다른 목적은 헬리코박터 파이로리균에 의해 발생하는 위질환을 예방 또는 개선할 수 있는 식품 조성물을 제조하는 방법을 제공하는데 있다.In addition, another object of the present invention is to provide a method of preparing a food composition capable of preventing or improving gastric diseases caused by Helicobacter pylori.
또한, 본 발명의 또 다른 목적은 엉겅퀴, 민들레, 양배추, 꿀 및 생강으로 이루어진 혼합물을 함유하여 헬리코박터 파이로리균에 의해 발생하는 위질환을 예방 또는 치료할 수 있는 식품 조성물을 제공하는데 있다.In addition, another object of the present invention is to provide a food composition capable of preventing or treating gastric diseases caused by Helicobacter pylori by containing a mixture consisting of thistle, dandelion, cabbage, honey and ginger.
상기한 목적을 달성하기 위한 본 발명의 헬리코박터 파이로리균에 의해 발생하는 위질환의 예방 또는 개선용 식품 조성물은 엉겅퀴 및 민들레로 이루어진 혼합물을 추출한 혼합 추출물; 양배추 추출물; 꿀; 생강즙; 및 스테비아로 이루어진 혼합물을 유효성분으로 함유할 수 있다.The food composition for preventing or improving gastric diseases caused by Helicobacter pylori of the present invention for achieving the above object comprises: a mixed extract obtained by extracting a mixture consisting of thistle and dandelion; Cabbage extract; honey; Ginger juice; And it may contain a mixture consisting of stevia as an active ingredient.
상기 혼합 추출물은 엉겅퀴와 민들레를 1 : 0.2-1의 중량비로 혼합하여 80 내지 100 ℃에서 추출한 추출물일 수 있다.The mixed extract may be an extract extracted at 80 to 100° C. by mixing thistle and dandelion in a weight ratio of 1: 0.2-1.
상기 혼합 추출물 100 중량부에 대하여 양배추 추출물 1 내지 30 중량부, 꿀 0.5 내지 10 중량부, 생강즙 0.1 내지 5 중량부 및 스테비아 0.1 내지 5 중량부로 혼합될 수 있다.With respect to 100 parts by weight of the mixed extract, 1 to 30 parts by weight of cabbage extract, 0.5 to 10 parts by weight of honey, 0.1 to 5 parts by weight of ginger juice, and 0.1 to 5 parts by weight of stevia may be mixed.
상기 헬리코박터 파이로리균에 의해 발생하는 위질환은 헬리코박터 파이로리균에 의해 발생하는 급성 위염, 만성위염, 위궤양, 십이지장 궤양, 위암 및 위림프종으로 이루어진 군에서 선택되는 1 이상의 위질환일 수 있다.The gastric disease caused by Helicobacter pylori may be at least one gastric disease selected from the group consisting of acute gastritis, chronic gastritis, gastric ulcer, duodenal ulcer, gastric cancer and gastric lymphoma caused by Helicobacter pylori.
상기 엉겅퀴는 엉겅퀴의 꽃, 줄기와 잎의 혼합물, 및 뿌리가 1 : 14-25 : 0.1-0.9의 중량비로 혼합한 것일 수 있다.The thistle may be a mixture of flowers of thistle, a mixture of stems and leaves, and roots in a weight ratio of 1: 14-25: 0.1-0.9.
또한, 상기한 다른 목적을 달성하기 위한 헬리코박터 파이로리균에 의해 발생하는 위질환의 예방 또는 개선용 식품 조성물의 제조방법은 (A) 엉겅퀴 및 민들레를 혼합하여 추출함으로써 혼합 추출물을 수득하는 단계; (B) 상기 혼합 추출물에 양배추 추출물 및 생강즙을 첨가하여 혼합하는 단계; 및 (C) 상기 양배추 추출물 및 생강즙이 혼합된 혼합물에 꿀 및 스테비아를 첨가하여 혼합하는 단계;를 포함할 수 있다.In addition, a method for preparing a food composition for preventing or improving gastric diseases caused by Helicobacter pylori to achieve the other object described above includes the steps of (A) obtaining a mixed extract by mixing and extracting thistle and dandelion; (B) adding and mixing cabbage extract and ginger juice to the mixed extract; And (C) adding and mixing honey and stevia to the mixture of the cabbage extract and ginger juice.
또한, 상기한 또 다른 목적을 달성하기 위한 본 발명의 헬리코박터 파이로리균에 의해 발생하는 위질환의 예방 또는 치료용 약학 조성물은 엉겅퀴 및 민들레로 이루어진 혼합물을 추출한 혼합 추출물; 양배추 추출물; 꿀; 생강즙; 및 스테비아로 이루어진 혼합물을 유효성분으로 함유할 수 있다.In addition, the pharmaceutical composition for the prevention or treatment of gastric diseases caused by Helicobacter pylori of the present invention for achieving the another object described above is a mixed extract obtained by extracting a mixture consisting of thistle and dandelion; Cabbage extract; honey; Ginger juice; And it may contain a mixture consisting of stevia as an active ingredient.
본 발명의 헬리코박터 파이로리균에 의해 발생하는 위질환의 예방, 치료 또는 개선용 조성물은 헬리코박터 파이로리균의 생육을 억제시켜 급성 위염, 만성위염, 위궤양, 십이지장 궤양, 위암 및 위림프종으로 이루어진 군에서 선택되는 1 이상의 헬리코박터 파이로리균에 의해 발생하는 위질환을 예방, 치료 또는 개선할 수 있으며, 독성이 없으므로 식품의 형태로 섭취할 수 있다.The composition for preventing, treating or improving gastric diseases caused by Helicobacter pylori of the present invention is selected from the group consisting of acute gastritis, chronic gastritis, gastric ulcer, duodenal ulcer, gastric cancer and gastric lymphoma by inhibiting the growth of Helicobacter pylori. It can prevent, treat or ameliorate gastric diseases caused by one or more Helicobacter pylori, and since it is not toxic, it can be consumed in the form of food.
본 발명은 엉겅퀴, 민들레, 양배추 꿀 및 생강으로 이루어진 혼합물을 함유하는 헬리코박터 파이로리균에 의해 발생하는 위질환의 예방, 치료 또는 개선용 조성물에 관한 것이다.The present invention relates to a composition for preventing, treating or improving gastric diseases caused by Helicobacter pylori containing a mixture consisting of thistle, dandelion, cabbage honey and ginger.
상기 헬리코박터 파이로리균에 의해 발생하는 위질환은 헬리코박터 파이로리균에 의해 발생하는 급성 위염, 만성위염, 위궤양, 십이지장 궤양, 위암 및 위림프종으로 이루어진 군에서 선택되는 1 이상의 위질환일 수 있다.
The gastric disease caused by Helicobacter pylori may be at least one gastric disease selected from the group consisting of acute gastritis, chronic gastritis, gastric ulcer, duodenal ulcer, gastric cancer and gastric lymphoma caused by Helicobacter pylori.
이하, 본 발명을 상세하게 설명한다. Hereinafter, the present invention will be described in detail.
본 발명의 헬리코박터 파이로리균에 의해 발생하는 위질환의 예방, 치료 또는 개선용 조성물은 엉겅퀴 및 민들레로 이루어진 혼합물을 추출한 혼합 추출물; 양배추 추출물; 꿀; 생강즙; 및 스테비아로 이루어진 혼합물을 유효성분으로 함유한다.The composition for preventing, treating, or improving gastric diseases caused by Helicobacter pylori of the present invention comprises: a mixed extract obtained by extracting a mixture consisting of thistle and dandelion; Cabbage extract; honey; Ginger juice; And a mixture consisting of stevia as an active ingredient.
엉겅퀴Thistle
본 발명에 사용되는 상기 엉겅퀴는 흰무늬 엉겅퀴(Silybum marianum (L.) Gaertn.), 가시 엉겅퀴(Cirsium japonicum Fisch ex DC. var. spinossimum Kitam.) 또는 이들의 혼합물일 수 있으며, 바람직하게는 흰무늬 엉겅퀴 단독을 이용하는 것이다.The thistle used in the present invention may be white-patterned thistle (Silybum marianum (L.) Gaertn.), spiny thistle (Cirsium japonicum Fisch ex DC. var. spinossimum Kitam.), or a mixture thereof, preferably white-patterned thistle. It is to use thistle alone.
상기 흰무늬 엉겅퀴(Silybum marianum (L.) Gaertn.)는 우유같이 하얀 잎맥과 함께 깊고 반짝이는 녹색의 식물이며, 가장자리에는 물결무늬가 있고 가시도 있는 뿌리-잎사귀로 분할되는 가늘고 긴 식물이다. 이것은 제방 울타리와 버려진 땅에서 주로 발견된다. 식물의 유용한 부분은 허브 전체, 뿌리, 잎사귀, 씨, 그리고 겉껍질이며, 엉겅퀴 씨는 실리마린으로 알려진 플라보노이드(flavonoid) 화합물을 함유하고 있다. 엉겅퀴 씨 추출물에는 70~80%의 실리마린이 함유되어 있다.The white-patterned thistle (Silybum marianum (L.) Gaertn.) is a deep, shiny green plant with milky white veins, and is a long, elongated plant divided into root-leaves with wavy patterns and thorns at the edges. It is mainly found in levee fences and in abandoned land. Useful parts of plants are whole herbs, roots, leaves, seeds, and shells, and thistle seeds contain a flavonoid compound known as silymarin. Thistle seed extract contains 70-80% silymarin.
본 발명에 따른 엉겅퀴는 엉겅퀴의 꽃, 줄기와 잎의 혼합물, 및 뿌리가 혼합된 혼합 추출물이다.Thistle according to the present invention is a mixed extract of a thistle flower, a mixture of stems and leaves, and a mixture of roots.
상기 엉겅퀴의 꽃은 꽃부리가 자주색 또는 적색이며 길이가 19-24 mm로서, 길이가 10 내지 15 mm인 것만 사용하고 그 이상 길이가 긴 것은 사용하지 않는 것이 독성에 바람직하다.The flowers of thistle are purple or red corolla and 19-24 mm in length, and it is preferable to use only those having a length of 10 to 15 mm and not use those with a length longer than that.
또한, 상기 엉겅퀴 줄기와 잎은 1 : 1-4의 중량비, 바람직하게는 1 : 2-3의 중량비로 혼합하여 사용한다. 줄기를 기준으로 잎의 함량이 상기 하한치 미만인 경우에는 쓴맛이 강할 수 있으며, 상기 상한치 초과인 경우에는 헬리코박터 파이로리균에 의해 발생하는 위질환의 예방, 치료 또는 개선에 바람직하지 않다.In addition, the thistle stem and leaves are used by mixing in a weight ratio of 1: 1-4, preferably in a weight ratio of 1: 2-3. If the content of leaves based on the stem is less than the lower limit, the bitter taste may be strong, and if the content of the leaves is greater than the upper limit, it is not preferable for the prevention, treatment, or improvement of gastric diseases caused by Helicobacter pylori.
또한, 상기 엉겅퀴 뿌리는 1년에 2번 수확하는 꽃, 줄기 및 잎과 달리 3년에 1번 수확하므로 건조하여 사용하는 것이 바람직하다.In addition, the thistle root is harvested once every three years, unlike flowers, stems, and leaves that are harvested twice a year, so it is preferable to use it after drying.
상기 엉겅퀴의 꽃, 줄기와 잎의 혼합물, 및 뿌리는 1 : 14-25 : 0.1-0.9의 중량비, 바람직하게는 1 : 16-19 : 0.4-0.8의 중량비로 혼합된다. 꽃을 기준으로 줄기와 잎의 혼합물, 및 뿌리의 함량이 상기 하한치 미만인 경우에는 헬리코박터 파이로리균에 의해 발생하는 위질환의 예방, 치료 또는 개선에 대한 효과가 우수하지 못할 수 있으며, 상기 상한치 초과인 경우에는 쓴맛이 강하고 헬리코박터 파이로리균에 의해 발생하는 위질환의 예방, 치료 또는 개선에 대한 효과가 저하될 수 있다. The flower of thistle, a mixture of stems and leaves, and roots are mixed in a weight ratio of 1: 14-25: 0.1-0.9, preferably 1: 16-19: 0.4-0.8. If the content of stem and leaf mixture and root based on flowers is less than the lower limit, the effect on preventing, treating, or improving gastric diseases caused by Helicobacter pylori may not be excellent, and if it exceeds the upper limit. There is a strong bitter taste, and the effect on the prevention, treatment, or improvement of gastric diseases caused by Helicobacter pylori may be reduced.
본 발명의 상기 엉겅퀴 혼합 추출물은 80 내지 100 ℃에서 20 내지 30시간, 바람직하게는 24 내지 28시간 동안 추출한 중탕 추출물이다. 추출 온도 및 시간이 상기 하한치 미만인 경우에는 유효성분이 추출되지 않을 수 있으며, 상기 상한치 초과인 경우에는 탄맛이 강하고 영양성분이 파괴될 수 있다. 또한, 물을 사용하는 중탕 추출 외에 유기 용매 추출 등의 다른 방식으로 추출을 수행하는 경우에는 헬리코박터 파이로리균에 의해 발생하는 위질환의 예방, 치료 또는 개선에 대한 효과가 미미하며 쓴맛이 강하게 발생할 수 있다. The mixed extract of thistle of the present invention is an extract extracted for 20 to 30 hours, preferably 24 to 28 hours at 80 to 100 ℃. When the extraction temperature and time are less than the lower limit, the active ingredient may not be extracted, and when the extraction temperature and time exceed the upper limit, the tan taste may be strong and the nutrient component may be destroyed. In addition, when extraction is performed in other ways, such as organic solvent extraction, in addition to the water bath extraction, the effect of preventing, treating or improving gastric diseases caused by Helicobacter pylori bacteria may be insignificant, and a strong bitter taste may occur. .
구체적으로, 상기 엉겅퀴 혼합 추출물은 꽃, 및 줄기와 잎의 혼합물을 혼합하여 중탕 추출하고, 별도로 뿌리를 중탕 추출하여 추후에 혼합한다. 본 발명과 달리, 꽃, 줄기와 잎의 혼합물 및 뿌리를 모두 혼합하여 중탕 추출하는 경우에는 쓴맛이 강하고 오히려 헬리코박터 파이로리균에 의해 발생하는 위질환의 예방, 치료 또는 개선에 대한 효과가 저하될 수 있다.Specifically, the mixed extract of thistle is mixed with flowers, and a mixture of stems and leaves, followed by extraction with a bath, and separate roots are extracted with a bath, followed by mixing. Unlike the present invention, in the case of extracting the bath by mixing flowers, a mixture of stems and leaves, and roots, the bitter taste is strong, and the effect on the prevention, treatment, or improvement of gastric diseases caused by Helicobacter pylori bacteria may be lowered. .
이러한 엉겅퀴 혼합 추출물을 제조하는 방법은 구체적으로 (a) 엉겅퀴의 꽃, 및 줄기와 잎의 혼합물을 혼합하여 80 내지 100 ℃에서 중탕 추출하여 추출물을 수득하는 단계; (b) 엉겅퀴의 뿌리를 80 내지 100 ℃에서 중탕 추출하여 추출물을 수득하는 단계; 및 (c) 상기 (a)단계 및 (b)단계에서 수득된 추출물을 각각 동결건조하여 분말화하여 혼합하는 단계;를 포함할 수 있다. 또한, 상기 (c)단계 이후에, (d) 상기 (b)단계에서 추출하고 남은 잔사를 건조하여 분쇄하는 단계; 및 (e) 상기 (c)단계에서 혼합된 분말 100 중량부와 (d)단계의 분말 0.1 내지 3 중량부를 혼합하는 단계;를 더 포함할 수 있다.Specifically, the method of preparing the mixed thistle extract includes the steps of: (a) mixing a mixture of flowers of thistle, and a mixture of stems and leaves, and extracting the extract by boiling water at 80 to 100° C. to obtain an extract; (b) extracting the roots of thistle in a bath at 80 to 100° C. to obtain an extract; And (c) lyophilizing and powdering the extracts obtained in steps (a) and (b), respectively, and mixing them. In addition, after the step (c), (d) drying and pulverizing the residue extracted in the step (b); And (e) mixing 100 parts by weight of the powder mixed in step (c) with 0.1 to 3 parts by weight of the powder in step (d).
상기 (a) 및 (b)단계와 달리, 꽃, 줄기와 잎의 혼합물, 및 뿌리를 모두 혼합하여 중탕 추출하는 경우에는 쓴맛이 강하고 오히려 헬리코박터 파이로리균에 의해 발생하는 위질환의 예방, 치료 또는 개선에 대한 효과가 저하될 수 있으며; 꽃, 줄기와 잎의 혼합물, 및 뿌리를 모두 각각 중탕 추출하는 경우에는 수율이 저하될 수 있다.Unlike steps (a) and (b) above, in the case of mixing flowers, a mixture of stems and leaves, and all of the roots and extracting the bath, the bitter taste is strong, but rather, the prevention, treatment or improvement of gastric diseases caused by Helicobacter pylori The effect on may be reduced; When the flowers, the mixture of stems and leaves, and the roots are all extracted in a bath, the yield may decrease.
상기 (D)단계에서 제조된 뿌리 잔사 분말을 첨가하는 경우에는 상기 뿌리 잔사 분말을 첨가하지 않는 경우에 비하여 질환에 대한 효과가 월등히 향상될 수 있다.When the root residue powder prepared in step (D) is added, the effect on diseases can be significantly improved compared to the case where the root residue powder is not added.
민들레dandelion
상기 민들레(Taraxacum platycarpum)는 금잠초, 지정, 포공영, 포공초, 안질방이라고도 하며 앉은뱅이라는 별명도 있다. 잎 또는 줄기에는 단백질, 탄수화물, 지방, 회분, 무기질, 비타민 등이 골고루 함유되어 있다. 어린순은 나물이나 국거리로 쓴다. 한방에서는 뿌리와 꽃피기 전의 전초를 해열, 소염, 이뇨, 건위의 효능이 있다고 하여, 감모발열, 인후염, 기관지염, 임파선염, 안질, 유선염, 간염, 담낭염, 소화불량, 소변불리, 변비의 치료제로 이용한다.The dandelion (Taraxacum platycarpum) is also referred to as Geumjamcho, Jeongji, Pogongyeong, Pogongcho, Anjilbang, and also has the nickname of Satbang. Leaves or stems evenly contain proteins, carbohydrates, fats, ash, minerals, and vitamins. Young shoots are used as herbs or soup. In oriental medicine, the roots and outposts before flowering are said to be effective in antipyretic, anti-inflammatory, diuretic, and dry stomach. Use.
본 발명에서 엉겅퀴와 민들레는 1 : 0.2-1의 중량비, 바람직하게는 1 : 0.4-0.6의 중량비로 혼합된다. In the present invention, thistle and dandelion are mixed in a weight ratio of 1:0.2-1, preferably 1:0.4-0.6.
엉겅퀴를 기준으로 민들레의 함량이 상기 하한치 미만인 경우에는 헬리코박터 파이로리균에 의해 발생하는 위질환의 예방, 치료 또는 개선하는 효과가 각 물질을 단독으로 사용하는 경우보다도 낮을 수 있으며, 상기 상한치 초과인 경우에는 헬리코박터 파이로리균에 의해 발생하는 위질환의 예방, 치료 또는 개선하는 효과가 거의 없을 수 있다. If the content of dandelion based on thistle is less than the above lower limit, the effect of preventing, treating, or improving gastric diseases caused by Helicobacter pylori may be lower than when each substance is used alone, and if it exceeds the upper limit, It may have little effect to prevent, treat, or ameliorate gastric diseases caused by Helicobacter pylori.
본 발명의 엉겅퀴 및 민들레가 혼합된 혼합 추출물은 엉겅퀴 및 민들레의 혼합물과 추출용매를 1 : 1 내지 100의 중량비, 바람직하게는 1 : 5 내지 20의 중량비로 혼합하여 80 내지 100 ℃에서 40 내지 50시간 동안 추출하여 추출물을 제조한다. 상기 혼합물과 추출용매의 중량비가 상기 범위를 벗어나는 경우에는 추출물에 엉겅퀴 및 민들레 혼합물의 유효성분이 적은 양으로 추출될 수 있다.The mixed extract of thistle and dandelion of the present invention is a mixture of thistle and dandelion and an extraction solvent in a weight ratio of 1: 1 to 100, preferably 1: 5 to 20, at 80 to 100° C. and 40 to 50 Extract for an hour to prepare an extract. When the weight ratio of the mixture and the extraction solvent is out of the above range, the active ingredient of thistle and dandelion mixture may be extracted in a small amount in the extract.
상기 추출물을 추출하는 추출용매는 물, 탄소수 1 내지 4의 저급알코올 또는 이들의 혼합용매이다. 상기 추출용매로는 특별히 한정하는 것은 아니지만 물로 추출된 추출물이 우수한 효과를 보인다.The extraction solvent for extracting the extract is water, a lower alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof. The extraction solvent is not particularly limited, but the extract extracted with water exhibits an excellent effect.
양배추 추출물Cabbage extract
상기 양배추(Cabbage)는 잎이 두껍고 털이 없으며 분처럼 흰빛이 돌고 가장자리에 불규칙한 톱니가 있으며 주름이 있어 서로 겹쳐지고 가장 안쪽에 있는 잎은 공처럼 둥글며 단단한 것으로서, 건강을 돕는데 효력이 있으며, 암 예방, 혈액순환, 해독작용, 변비 개선 등의 효능이 있다.Cabbage has thick leaves, no hair, turns white like a powder, irregular serrations at the edges, wrinkles, and overlaps each other, and the innermost leaves are round and hard like a ball, and are effective in helping health, preventing cancer, It is effective in improving blood circulation, detoxification, and constipation.
상기 양배추 추출물은 상기 혼합 추출물 100 중량부에 대하여 1 내지 30 중량부, 바람직하게는 5 내지 15 중량부로 사용된다. 양배추 추출물의 함량이 상기 하한치 미만인 경우에는 헬리코박터 파이로리균에 의해 발생하는 위질환의 예방, 치료 또는 개선하는 효과가 저하될 수 있으며, 상기 상한치 초과인 경우에는 관능성이 저하되며 헬리코박터 파이로리균에 의해 발생하는 위질환의 예방, 치료 또는 개선하는 효과가 각 물질을 단독으로 사용하는 경우보다도 낮을 수 있다.The cabbage extract is used in an amount of 1 to 30 parts by weight, preferably 5 to 15 parts by weight, based on 100 parts by weight of the mixed extract. If the content of cabbage extract is less than the lower limit, the effect of preventing, treating, or improving gastric diseases caused by Helicobacter pylori may be reduced, and if it exceeds the upper limit, the organoleptic is lowered and is caused by Helicobacter pylori. The effect of preventing, treating or ameliorating gastric diseases may be lower than when each substance is used alone.
본 발명의 양배추 추출물은 양배추와 추출용매를 1 : 1 내지 100의 중량비, 바람직하게는 1 : 5 내지 20의 중량비로 혼합하여 80 내지 100 ℃에서 8 내지 15시간, 바람직하게는 10 내지 12시간 동안 중탕 추출하여 제조한다. 상기 혼합물과 추출용매의 중량비가 상기 범위를 벗어나는 경우에는 추출물에 양배추의 유효성분이 적은 양으로 추출될 수 있다.Cabbage extract of the present invention is a mixture of cabbage and extraction solvent in a weight ratio of 1: 1 to 100, preferably 1: 5 to 20, at 80 to 100 °C for 8 to 15 hours, preferably 10 to 12 hours It is prepared by extracting from the bath. When the weight ratio of the mixture and the extraction solvent is out of the above range, the active ingredient of cabbage may be extracted in a small amount in the extract.
상기 추출물을 추출하는 추출용매는 물, 탄소수 1 내지 4의 저급알코올 또는 이들의 혼합용매이다. 상기 추출용매로는 특별히 한정하는 것은 아니지만 물로 추출된 추출물이 우수한 효과를 보인다.The extraction solvent for extracting the extract is water, a lower alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof. The extraction solvent is not particularly limited, but the extract extracted with water exhibits an excellent effect.
생강즙Ginger juice
상기 생강은 뿌리줄기로서, 옆으로 자라고 다육질이며 덩어리 모양이고 황색이며 매운 맛과 향긋한 냄새가 있다. 생강은 감기로 인한 오한, 발열, 두통, 구토, 해수, 가래를 치료하며 식중독으로 인한 복통설사, 복만에도 효과가 있어 끓는 물에 생강을 달여서 차로 마시기도 한다. 약리작용으로는 위액분비촉진, 소화력 증진, 심장흥분 작용, 혈액순환촉진, 억균작용 등이 보고되었다. The ginger is a rootstock, grows sideways, is fleshy, lumps, yellow, has a spicy taste and a fragrant smell. Ginger cures chills, fever, headache, vomiting, seawater, and phlegm caused by colds. It is also effective for abdominal pain, diarrhea and stomach caused by food poisoning. As pharmacological action, gastric juice secretion promotion, digestion enhancement, heart excitation, blood circulation promotion, and inhibition have been reported.
본 발명에서는 생강을 착즙한 후 고형분을 제거한 생강즙을 이용하는 것으로서, 추출물로 제조하여 사용시에는 헬리코박터 파이로리균에 의해 발생하는 위질환의 예방, 치료 또는 개선하는 효과가 저하될 수 있다.In the present invention, ginger juice from which solids are removed after the ginger is juiced, and when prepared as an extract and used, the effect of preventing, treating, or improving gastric diseases caused by Helicobacter pylori bacteria may be reduced.
또한, 상기 생강즙은 단독으로 사용시에는 헬리코박터 파이로리균에 의해 발생하는 위질환의 예방, 치료 또는 개선에 거의 효과가 없지만, 상기 엉겅퀴 및 민들레의 혼합 추출물 및 양배추 추출물과 함께 사용하면 생강즙 단독 또는 상기 혼합 추출물 단독으로 사용하는 경우에 비하여 1.5 내지 20배 우수한 효능을 보인다.In addition, when used alone, the ginger juice has little effect in preventing, treating or improving gastric diseases caused by Helicobacter pylori, but when used together with the mixed extract of thistle and dandelion and cabbage extract, ginger juice alone or the mixed extract Compared to the case of using alone, it exhibits 1.5 to 20 times superior efficacy.
상기 생강즙은 상기 혼합 추출물 100 중량부에 대하여 0.1 내지 5 중량부, 바람직하게는 0.5 내지 2 중량부로 사용된다. 생강즙의 함량이 상기 하한치 미만인 경우에는 헬리코박터 파이로리균에 의해 발생하는 위질환의 예방, 치료 또는 개선하는 효과가 저하될 수 있으며, 상기 상한치 초과인 경우에는 관능성이 저하될 수 있다.The ginger juice is used in an amount of 0.1 to 5 parts by weight, preferably 0.5 to 2 parts by weight, based on 100 parts by weight of the mixed extract. When the content of ginger juice is less than the lower limit, the effect of preventing, treating, or improving gastric diseases caused by Helicobacter pylori may be reduced, and when the content of the ginger juice exceeds the upper limit, the organoleptic property may be lowered.
꿀honey
상기 꿀은 단독으로 사용시에는 효과가 없으나, 상기 엉겅퀴 및 민들레의 혼합 추출물, 양배추 추출물 및 생강즙과 함께 사용하면 헬리코박터 파이로리균에 의해 발생하는 위질환의 예방, 치료 또는 개선에도 효과가 있다.The honey is not effective when used alone, but when used together with the mixed extract of thistle and dandelion, cabbage extract, and ginger juice, it is effective in preventing, treating, or improving gastric diseases caused by Helicobacter pylori.
상기 꿀은 혼합 추출물 100 중량부에 대하여 0.5 내지 10 중량부, 바람직하게는 2 내지 6 중량부로 사용된다. 꿀의 함량이 상기 하한치 미만인 경우에는 헬리코박터 파이로리균에 의해 발생하는 위질환의 예방, 치료 또는 개선의 효과가 없을 수 있으며, 상기 상한치 초과인 경우에는 관능성이 저하되고 제조비용이 향상될 수 있다. The honey is used in an amount of 0.5 to 10 parts by weight, preferably 2 to 6 parts by weight, based on 100 parts by weight of the mixed extract. When the content of honey is less than the lower limit, there may be no effect of preventing, treating, or improving gastric diseases caused by Helicobacter pylori, and when it exceeds the upper limit, organoleptic properties may decrease and manufacturing cost may be improved.
스테비아Stevia
상기 스테비아(Stevia rebaudiana)는 하천이나 습지대 주변에서 자라는 것으로서, 옛날부터 스테비아 잎을 감미료로 이용해 왔는데 최근 합성감미료인 사카린의 유해성이 문제가 되자, 다시 주목을 끌게 되었다. 잎에는 무게의 6~7% 정도 감미물질인 스테비오시드(stevioside)가 들어 있는데, 상기 함유율은 개체에 따라 차이가 크다. 감미성분은 설탕의 300배로서, 차를 만들어 마시거나 껌 대용으로 하며 청량음료의 감미료로 사용한다. Stevia ( Stevia rebaudiana ) grows around rivers or wetlands, and has been using stevia leaves as a sweetener from ancient times. Recently, when the harmfulness of saccharin, a synthetic sweetener, became a problem, it attracted attention again. Leaves contain stevioside, a sweetening substance about 6-7% by weight, and the content varies greatly depending on the individual. The sweetening ingredient is 300 times that of sugar, and it is used as a sweetener in soft drinks and as a substitute for tea or chewing gum.
본 발명에서는 스테비아를 사용함으로써 생강즙의 사용에 의해 저하된 관능성을 높인다.In the present invention, the use of stevia enhances the functionality lowered by the use of ginger juice.
상기 스테비아는 혼합 추출물 100 중량부에 대하여 0.1 내지 5 중량부, 바람직하게는 0.2 내지 1 중량부로 사용된다. 스테비아의 함량이 상기 범위를 벗어나는 경우에는 관능성이 저하될 수 있다.The stevia is used in an amount of 0.1 to 5 parts by weight, preferably 0.2 to 1 parts by weight, based on 100 parts by weight of the mixed extract. If the content of stevia is out of the above range, the functionality may be lowered.
또한, 본 발명은 헬리코박터 파이로리균에 의해 발생하는 위질환의 예방, 치료 또는 개선용 조성물을 제조하는 방법을 제공한다.In addition, the present invention provides a method of preparing a composition for preventing, treating or improving gastric diseases caused by Helicobacter pylori.
본 발명의 헬리코박터 파이로리균에 의해 발생하는 위질환의 예방, 치료 또는 개선용 조성물의 제조방법은 (A) 엉겅퀴 및 민들레를 혼합하여 추출함으로써 혼합 추출물을 수득하는 단계; (B) 상기 혼합 추출물에 양배추 추출물 및 생강즙을 첨가하여 혼합하는 단계; 및 (C) 상기 양배추 추출물 및 생강즙이 혼합된 혼합물에 꿀 및 스테비아를 첨가하여 혼합하는 단계;를 포함할 수 있다.The method for preparing a composition for preventing, treating, or improving gastric diseases caused by Helicobacter pylori of the present invention comprises the steps of: (A) obtaining a mixed extract by mixing and extracting milk thistle and dandelion; (B) adding and mixing cabbage extract and ginger juice to the mixed extract; And (C) adding and mixing honey and stevia to the mixture of the cabbage extract and ginger juice.
먼저, 상기 (A)단계에서는 엉겅퀴 및 민들레를 혼합한 혼합물을 추출용매로 추출하여 혼합 추출물을 수득한다.First, in step (A), a mixture of thistle and dandelion is extracted with an extraction solvent to obtain a mixed extract.
상기 혼합물의 혼합조건, 추출용매 및 추출조건은 상기에서 언급된 내용과 동일하다.The mixing conditions, extraction solvent and extraction conditions of the mixture are the same as those mentioned above.
다음으로, 상기 (B)단계에서는 상온(23-27 ℃)에서 상기 혼합 추출물에 양배추 추출물 및 생강즙을 첨가하여 양배추 추출물 및 생강즙이 혼합된 혼합물을 제조한다.Next, in step (B), a mixture of cabbage extract and ginger juice is prepared by adding cabbage extract and ginger juice to the mixed extract at room temperature (23-27° C.).
상기 (A)단계에서 엉겅퀴 및 민들레를 혼합하여 혼합 추출물을 제조 시 양배추 추출물 및 생강즙을 첨가하여 추출하지 않고 추후에 따로 양배추 추출물 및 생강즙을 첨가함으로써, 관능성을 높이며 헬리코박터 파이로리균에 의해 발생하는 위질환의 예방, 치료 또는 개선 효과를 더욱 향상시킬 수 있다. 엉겅퀴 및 민들레에 양배추 및 생강을 첨가하여 추출을 수행하는 경우에는 양배추 및 생강을 넣지 않은 경우에 비하여 헬리코박터 파이로리균에 의해 발생하는 위질환의 예방, 치료 또는 개선 효과가 향상되지 않으므로 엉겅퀴 및 민들레를 혼합한 혼합 추출물에 별도로 양배추 추출물 및 생강즙을 첨가하는 것이 바람직하다.When preparing the mixed extract by mixing thistle and dandelion in step (A), the cabbage extract and ginger juice are not added to extract the extract, but the cabbage extract and ginger juice are added separately to increase the organoleptic properties, and the stomach caused by the Helicobacter pylori bacteria. It is possible to further improve the effect of preventing, treating or ameliorating the disease. In the case of extraction by adding cabbage and ginger to thistle and dandelion, the effect of preventing, treating or improving gastric diseases caused by Helicobacter pylori is not improved compared to the case where cabbage and ginger are not added, so thistle and dandelion are mixed. It is preferable to separately add cabbage extract and ginger juice to one mixed extract.
다음으로, 상기 (C)단계에서는 상온에서 상기 양배추 추출물 및 생강즙이 혼합된 혼합물에 꿀 및 스테비아를 첨가하여 혼합한다. Next, in the step (C), honey and stevia are added to the mixture of the cabbage extract and ginger juice at room temperature and mixed.
상기 꿀 및 스테비아는 양배추 추출물 및 생강즙이 상기 혼합 추출물과 충분히 혼합된 후에 첨가되는데, 양배추 추출물, 생강즙, 꿀 및 스테비아를 동시에 첨가하여 혼합하는 경우에는 관능성이 현저히 저하될 수 있다.
The honey and stevia are added after the cabbage extract and ginger juice are sufficiently mixed with the mixed extract. When the cabbage extract, ginger juice, honey and stevia are added and mixed at the same time, the sensory properties may be significantly reduced.
본 발명 조성물의 형태는 젤, 퓨레, 즙, 환, 대환 및 과립의 형태로 제조될 수 있다.The form of the composition of the present invention may be prepared in the form of gels, purees, juices, pills, large rings, and granules.
일예로, 젤 및 퓨레의 형태로 제조되는 경우에는 상기 (B)단계에서 제조된 양배추 추출물 및 생강즙이 혼합된 혼합물을 농축기로 상기 혼합물의 부피 대비 1/3 내지 1/5의 부피로 농축시킨 후 상기 농축물을 이용하여 상기 (C)단계를 수행한다. 즉, 상기 농축물과 꿀 및 스테비아을 혼합한 후 한천을 첨가하여 교반한 다음 살균시켜 젤 및 퓨레를 제조한다. For example, in the case of manufacturing in the form of gel and puree, the mixture of cabbage extract and ginger juice prepared in step (B) is concentrated to a volume of 1/3 to 1/5 of the volume of the mixture with a concentrator. The (C) step is performed using the concentrate. That is, after mixing the concentrate with honey and stevia, agar is added, stirred, and then sterilized to prepare a gel and puree.
다른 예로, 즙의 형태로 제조되는 경우에는 상기 (C)단계에서 제조된 혼합물을 그대로 살균시켜 이용한다.As another example, when it is prepared in the form of juice, the mixture prepared in step (C) is sterilized and used as it is.
또 다른 예로, 환, 대환 및 과립의 형태로 제조되는 경우에는 상기 (B)단계에서 제조된 양배추 추출물 및 생강즙이 혼합된 혼합물을 농축기로 상기 혼합물의 부피 대비 1/5 내지 1/7의 부피로 농축시킨 후 상기 농축물에 꿀을 첨가하여 60 내지 70 ℃의 중탕기에서 40 내지 50시간 동안 숙성시킨 다음 건조시키고 성형하여 환, 대환 및 과립을 제조한다.
As another example, when prepared in the form of a pill, a stalk, and a granule, the mixture of the cabbage extract and ginger juice prepared in step (B) is used as a concentrator in a volume of 1/5 to 1/7 of the volume of the mixture. After concentration, honey is added to the concentrate, aged for 40 to 50 hours in a water bath at 60 to 70°C, dried, and molded to prepare rings, large rings, and granules.
본 발명의 혼합 추출물; 양배추 추출물; 꿀; 생강즙; 및 스테비아;로 이루어진 혼합물은 광의로는 혼합 추출물; 양배추 추출물; 꿀; 생강즙; 및 스테비아;로 이루어진 혼합물을 동물에게 투여할 수 있도록 제형화된 혼합 가공물, 예컨대, 혼합 추출물; 양배추 추출물; 꿀; 생강즙; 및 스테비아;의 혼합 분말도 포함하는 의미를 갖는다. 비록 본 발명에서 혼합 추출물; 양배추 추출물; 꿀; 생강즙; 및 스테비아;로 이루어진 혼합물로 실험을 진행하긴 하였으나, 혼합 추출물; 양배추 추출물; 꿀; 생강즙; 및 스테비아;의 혼합 가공물과 같은 형태로도 목적하는 효과를 달성할 수 있음은 당업자라면 예상가능할 것이다.Mixed extract of the present invention; Cabbage extract; honey; Ginger juice; And stevia; The mixture consisting of a mixed extract in a broad sense; Cabbage extract; honey; Ginger juice; And stevia; a mixed product formulated to be administered to an animal, such as a mixed extract; Cabbage extract; honey; Ginger juice; And Stevia; It has the meaning of including a mixed powder of. Although the mixed extract in the present invention; Cabbage extract; honey; Ginger juice; And stevia; although the experiment was conducted with a mixture consisting of, a mixed extract; Cabbage extract; honey; Ginger juice; And stevia; it will be predictable to those skilled in the art that the desired effect can be achieved even in the same form as the mixed product.
한편, 본 명세서에서 용어 '유효성분으로 함유하는'이란 혼합 추출물; 양배추 추출물; 꿀; 생강즙; 및 스테비아;로 이루어진 혼합물의 효능 또는 활성을 달성하는 데 충분한 양을 포함하는 것을 의미한다. 일예로, 상기 혼합 추출물; 양배추 추출물; 꿀; 생강즙; 및 스테비아;로 이루어진 혼합물은 10 내지 1500 ㎍/㎖, 바람직하게는 100 내지 1000 ㎍/㎖의 농도로 사용된다. 혼합 추출물; 양배추 추출물; 꿀; 생강즙; 및 스테비아;는 천연물로서 과량 투여하여도 인체에 부작용이 없으므로 본 발명의 조성물 내에 포함되는 혼합 추출물; 양배추 추출물; 꿀; 생강즙; 및 스테비아;의 양적 상한은 당업자가 적절한 범위 내에서 선택하여 실시할 수 있다.
Meanwhile, in the present specification, the term “contained as an active ingredient” is a mixed extract; Cabbage extract; honey; Ginger juice; And stevia; means containing an amount sufficient to achieve the efficacy or activity of a mixture consisting of. For example, the mixed extract; Cabbage extract; honey; Ginger juice; And stevia; the mixture is used in a concentration of 10 to 1500 µg/ml, preferably 100 to 1000 µg/ml. Mixed extract; Cabbage extract; honey; Ginger juice; And Stevia; is a natural product, even if administered in excess, since there is no side effect to the human body, the mixed extract contained in the composition of the present invention; Cabbage extract; honey; Ginger juice; And stevia; the upper limit of the quantity can be selected and carried out by a person skilled in the art within an appropriate range.
본 발명의 약제학적 조성물은 상기 유효 성분 이외에 약제학적으로 적합하고 생리학적으로 허용되는 보조제를 사용하여 제조될 수 있으며, 상기 보조제로는 부형제, 붕해제, 감미제, 결합제, 피복제, 팽창제, 윤활제, 활택제 또는 향미제 등을 사용할 수 있다.The pharmaceutical composition of the present invention may be prepared using a pharmaceutically suitable and physiologically acceptable adjuvant in addition to the active ingredient, and the adjuvants include excipients, disintegrants, sweeteners, binders, coating agents, expanding agents, lubricants, Lubricating agents or flavoring agents can be used.
상기 약제학적 조성물은 투여를 위해서 상기 기재한 유효 성분 이외에 추가로 약제학적으로 허용 가능한 담체를 1종 이상 포함하여 약제학적 조성물로 바람직하게 제제화할 수 있다.For administration, the pharmaceutical composition may contain one or more pharmaceutically acceptable carriers in addition to the above-described active ingredients, and may be preferably formulated into a pharmaceutical composition.
상기 약제학적 조성물의 제제 형태는 과립제, 산제, 정제, 피복정, 캡슐제, 좌제, 액제, 시럽, 즙, 현탁제, 유제, 점적제 또는 주사 가능한 액제 등이 될 수 있다. 예를 들어, 정제 또는 캡슐제의 형태로의 제제화를 위해, 유효 성분은 에탄올, 글리세롤, 물 등과 같은 경구, 무독성의 약제학적으로 허용 가능한 불활성 담체와 결합될 수 있다. 또한, 원하거나 필요한 경우, 적합한 결합제, 윤활제, 붕해제 및 발색제 또한 혼합물로 포함될 수 있다. 적합한 결합제는 이에 제한되는 것은 아니나, 녹말, 젤라틴, 글루코스 또는 베타-락토오스와 같은 천연 당, 옥수수 감미제, 아카시아, 트래커캔스 또는 소듐올레이트와 같은 천연 및 합성 검, 소듐 스테아레이트, 마그네슘 스테아레이트, 소듐 벤조에이트, 소듐 아세테이트, 소듐 클로라이드 등을 포함한다. 붕해제는 이에 제한되는 것은 아니나, 녹말, 메틸 셀룰로스, 아가, 벤토니트, 잔탄 검 등을 포함한다.The formulation form of the pharmaceutical composition may be granules, powders, tablets, coated tablets, capsules, suppositories, solutions, syrups, juices, suspensions, emulsions, drops, or injectable solutions. For example, for formulation in the form of tablets or capsules, the active ingredient may be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like. In addition, if desired or necessary, suitable binders, lubricants, disintegrants and coloring agents may also be included in the mixture. Suitable binders are, but are not limited to, natural sugars such as starch, gelatin, glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, trackcacanth or sodium oleate, sodium stearate, magnesium stearate, sodium Benzoate, sodium acetate, sodium chloride, and the like. Disintegrants include, but are not limited to, starch, methyl cellulose, agar, bentonite, xanthan gum, and the like.
액상 용액으로 제제화되는 조성물에 있어서 허용 가능한 약제학적 담체로는, 멸균 및 생체에 적합한 것으로서, 식염수, 멸균수, 링거액, 완충 식염수, 알부민 주사용액, 덱스트로즈 용액, 말토 덱스트린 용액, 글리세롤, 에탄올 및 이들 성분 중 1 성분 이상을 혼합하여 사용할 수 있으며, 필요에 따라 항산화제, 완충액, 정균제 등 다른 통상의 첨가제를 첨가할 수 있다. 또한 희석제, 분산제, 계면활성제, 결합제 및 윤활제를 부가적으로 첨가하여 수용액, 현탁액, 유탁액 등과 같은 주사용 제형, 환약, 캡슐, 과립 또는 정제로 제제화할 수 있다.Acceptable pharmaceutical carriers for compositions formulated as liquid solutions are sterilized and biocompatible, and include saline, sterile water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, ethanol, and One or more of these components may be mixed and used, and other conventional additives such as antioxidants, buffers, and bacteriostatic agents may be added as necessary. In addition, diluents, dispersants, surfactants, binders, and lubricants may be additionally added to prepare injection formulations such as aqueous solutions, suspensions, emulsions, etc., pills, capsules, granules, or tablets.
더 나아가 해당분야의 적절한 방법으로 Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA에 개시되어 있는 방법을 이용하여 각 질환에 따라 또는 성분에 따라 바람직하게 제제화할 수 있다.Further, it can be preferably formulated according to each disease or ingredient using a method disclosed in Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA as an appropriate method in the field.
본 발명의 약제학적 조성물은 경구 또는 비경구로 투여할 수 있고, 비경구 투여인 경우에는 정맥내 주입, 피하 주입, 근육 주입, 복강 주입, 경피 투여 등으로 투여할 수 있으며, 바람직하게는 경구 투여이다.The pharmaceutical composition of the present invention may be administered orally or parenterally, and in the case of parenteral administration, it may be administered by intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, transdermal administration, etc., preferably oral administration. .
본 발명의 약제학적 조성물의 적합한 투여량은 제제화 방법, 투여 방식, 환자의 연령, 체중, 성, 병적 상태, 음식, 투여 시간, 투여 경로, 배설 속도 및 반응 감응성과 같은 요인들에 의해 다양하며, 보통으로 숙련된 의사는 소망하는 치료 또는 예방에 효과적인 투여량을 용이하게 결정 및 처방할 수 있다. 본 발명의 바람직한 구현예에 따르면, 본 발명의 약제학적 조성물의 1일 투여량은 0.001-10 g/㎏이다.A suitable dosage of the pharmaceutical composition of the present invention varies depending on factors such as formulation method, mode of administration, age, weight, sex, pathological condition, food, administration time, route of administration, excretion rate and response sensitivity of the patient, Usually the skilled practitioner can readily determine and prescribe a dosage effective for the desired treatment or prophylaxis. According to a preferred embodiment of the present invention, the daily dosage of the pharmaceutical composition of the present invention is 0.001-10 g/kg.
본 발명의 약제학적 조성물은 당해 발명이 속하는 기술분야에서 통상의 지식을 가진 자가 용이하게 실시할 수 있는 방법에 따라, 약제학적으로 허용되는 담체 및/또는 부형제를 이용하여 제제화함으로써 단위 용량 형태로 제조되거나 또는 다용량 용기 내에 내입시켜 제조될 수 있다. 이때 제형은 오일 또는 수성 매질중의 용액, 현탁액 또는 유화액 형태이거나 엑스제, 분말제, 과립제, 정제 또는 캅셀제 형태일 수도 있으며, 분산제 또는 안정화제를 추가적으로 포함할 수 있다.The pharmaceutical composition of the present invention is prepared in unit dosage form by formulating using a pharmaceutically acceptable carrier and/or excipient according to a method that can be easily carried out by a person having ordinary knowledge in the art. Or it can be prepared by incorporating it into a multi-dose container. In this case, the formulation may be in the form of a solution, suspension or emulsion in an oil or aqueous medium, or may be in the form of an extract, powder, granule, tablet or capsule, and may additionally include a dispersant or a stabilizer.
또한, 본 발명은 혼합 추출물; 양배추 추출물; 꿀; 생강즙; 및 스테비아;로 이루어진 혼합물을 유효성분으로 함유하는 헬리코박터 파이로리균에 의해 발생하는 위질환의 예방, 치료 또는 개선용 식품 조성물을 제공한다.In addition, the present invention is a mixed extract; Cabbage extract; honey; Ginger juice; And Stevia; It provides a food composition for preventing, treating or improving gastric diseases caused by Helicobacter pylori containing a mixture consisting of as an active ingredient.
본 발명에 따른 식품 조성물은 상기 약제학적 조성물과 동일한 방식으로 제제화되어 기능성 식품으로 이용하거나, 각종 식품에 첨가할 수 있다. 본 발명의 조성물을 첨가할 수 있는 식품으로는 예를 들어, 음료류, 알코올 음료류, 과자류, 다이어트바, 유제품, 육류, 초코렛, 피자, 라면, 기타 면류, 껌류, 아이스크림류, 비타민 복합제, 건강보조식품류 등이 있다.The food composition according to the present invention may be formulated in the same manner as the pharmaceutical composition and used as a functional food or added to various foods. Foods to which the composition of the present invention can be added include, for example, beverages, alcoholic beverages, confectionery, diet bars, dairy products, meat, chocolate, pizza, ramen, other noodles, gums, ice creams, vitamin complexes, health supplements. Etc.
본 발명의 식품 조성물은 유효성분으로서 혼합 추출물; 양배추 추출물; 꿀; 생강즙; 및 스테비아;뿐만 아니라, 식품 제조 시에 통상적으로 첨가되는 성분을 포함할 수 있으며, 예를 들어, 단백질, 탄수화물, 지방, 영양소, 조미제 및 향미제를 포함한다. 상술한 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스, 올리고당 등; 및 폴리사카라이드, 예를 들어 덱스트린, 사이클로덱스트린 등과 같은 통상적인 당 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 향미제로서 천연 향미제 [타우마틴, 스테비아 추출물 (예를 들어 레바우디오시드 A, 글리시르히진 등]) 및 합성 향미제(사카린, 아스파르탐 등)를 사용할 수 있다. 예컨대, 본 발명의 식품 조성물이 드링크제와 음료류로 제조되는 경우에는 본 발명의 혼합 추출물; 배즙; 및 꿀 이외에 구연산, 액상과당, 설탕, 포도당, 초산, 사과산, 과즙, 및 각종 식물 추출액 등을 추가로 포함시킬 수 있다.The food composition of the present invention is a mixed extract as an active ingredient; Cabbage extract; honey; Ginger juice; And stevia; In addition, may include ingredients that are commonly added during food production, and include, for example, proteins, carbohydrates, fats, nutrients, flavoring agents, and flavoring agents. Examples of the aforementioned carbohydrates include monosaccharides such as glucose, fructose, and the like; Disaccharides such as maltose, sucrose, oligosaccharides, and the like; And polysaccharides, for example, common sugars such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents, natural flavoring agents [taumatin, stevia extract (eg, rebaudioside A, glycyrrhizin, etc.]) and synthetic flavoring agents (saccharin, aspartame, etc.) can be used. For example, when the food composition of the present invention is made of drinks and beverages, the mixed extract of the present invention; Pear juice; In addition to honey, citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, fruit juice, and various plant extracts may be further included.
본 발명은 상기 혼합 추출물; 양배추 추출물; 꿀; 생강즙; 및 스테비아;를 유효성분으로 포함하는 헬리코박터 파이로리균에 의해 발생하는 위질환의 예방, 치료 또는 개선용 식품 조성물을 포함하는 건강기능식품을 제공한다. 건강기능식품이란, 혼합 추출물; 양배추 추출물; 꿀; 생강즙; 및 스테비아;를 음료, 차류, 향신료, 껌, 과자류 등의 식품소재에 첨가하거나, 캡슐화, 분말화, 현탁액 등으로 제조한 식품으로, 이를 섭취할 경우 건강상 특정한 효과를 가져오는 것을 의미하나, 일반 약품과는 달리 식품을 원료로 하여 약품의 장기 복용시 발생할 수 있는 부작용 등이 없는 장점이 있다. 이와 같이 하여 얻어지는 본 발명의 건강기능식품은, 일상적으로 섭취하는 것이 가능하기 때문에 매우 유용하다. 이와 같은 건강기능식품에 있어서의 혼합 추출물; 양배추 추출물; 꿀; 생강즙; 및 스테비아;의 첨가량은, 대상인 건강기능식품의 종류에 따라 달라 일률적으로 규정할 수 없지만, 식품 본래의 맛을 손상시키지 않는 범위에서 첨가하면 되며, 대상 식품에 대하여 통상 0.01 내지 50 중량%, 바람직하기로는 0.1 내지 20 중량%의 범위이다. 또한, 환제, 과립제, 정제 또는 캡슐제 형태의 건강기능식품의 경우에는 통상 0.1 내지 100 중량% 바람직하기로는 0.5 내지 80 중량%의 범위에서 첨가하면 된다. 한 구체예에서, 본 발명의 건강기능식품은 환제, 정제, 캡슐제 또는 음료의 형태일 수 있다.The present invention is the mixed extract; Cabbage extract; honey; Ginger juice; And Stevia; It provides a health functional food comprising a food composition for the prevention, treatment or improvement of gastric diseases caused by Helicobacter pylori containing as an active ingredient. What is a health functional food, mixed extract; Cabbage extract; honey; Ginger juice; And stevia; added to food materials such as beverages, teas, spices, chewing gum, confectionery, etc., or are foods prepared as encapsulated, powdered, or suspended, and when ingested, it means bringing a specific effect on health. Unlike drugs, it has the advantage of not having side effects that may occur when taking drugs for a long time because food is used as a raw material. The health functional food of the present invention obtained in this way is very useful because it can be consumed on a daily basis. Mixed extracts in such health functional foods; Cabbage extract; honey; Ginger juice; And stevia; the amount of addition can not be uniformly defined depending on the type of health functional food to be targeted, but may be added within a range that does not impair the original taste of the food, and is usually 0.01 to 50% by weight, preferably, based on the target food. Is in the range of 0.1 to 20% by weight. In addition, in the case of health functional foods in the form of pills, granules, tablets or capsules, it is usually added in the range of 0.1 to 100% by weight, preferably 0.5 to 80% by weight. In one embodiment, the health functional food of the present invention may be in the form of a pill, tablet, capsule or beverage.
또한, 본 발명은 헬리코박터 파이로리균에 의해 발생하는 위질환의 예방, 치료 또는 개선용 의약 또는 식품의 제조를 위한 혼합 추출물; 양배추 추출물; 꿀; 생강즙; 및 스테비아의 용도를 제공한다. 상기한 바와 같이 혼합 추출물; 양배추 추출물; 꿀; 생강즙; 및 스테비아는 헬리코박터 파이로리균에 의해 발생하는 위질환을 위한 용도로 이용될 수 있다.In addition, the present invention is a mixed extract for the manufacture of a drug or food for the prevention, treatment or improvement of gastric diseases caused by Helicobacter pylori; Cabbage extract; honey; Ginger juice; And the use of stevia. Mixed extract as described above; Cabbage extract; honey; Ginger juice; And stevia may be used for gastric diseases caused by Helicobacter pylori.
또한, 본 발명은 포유동물에게 유효량의 혼합 추출물; 양배추 추출물; 꿀; 생강즙; 및 스테비아의 혼합물을 투여하는 것을 포함하는 헬리코박터 파이로리균에 의해 발생하는 위질환의 개선, 예방 또는 치료 방법을 제공한다.In addition, the present invention is a mixed extract of an effective amount to a mammal; Cabbage extract; honey; Ginger juice; And it provides a method of improving, preventing or treating gastric diseases caused by Helicobacter pylori comprising administering a mixture of stevia.
여기에서 사용된 용어 "포유동물"은 치료, 관찰 또는 실험의 대상인 포유동물을 말하며, 바람직하게는 인간을 말한다.The term "mammal" as used herein refers to a mammal that is an object of treatment, observation or experiment, and preferably refers to a human.
여기에서 사용된 용어 "유효량"은 연구자, 수의사, 의사 또는 기타 임상의에 의해 생각되는 조직계, 동물 또는 인간에서 생물학적 또는 의학적 반응을 유도하는 유효 성분 또는 약학적 조성물의 양을 의미하는 것으로, 이는 해당 질환 또는 장애의 증상의 완화를 유도하는 양을 포함한다. 본 발명의 유효 성분에 대한 유효량 및 투여횟수는 원하는 효과에 따라 변화될 것임은 당업자에게 자명하다. 그러므로, 투여될 최적의 투여량은 당업자에 의해 쉽게 결정될 수 있으며, 질환의 종류, 질환의 중증도, 조성물에 함유된 유효성분 및 다른 성분의 함량, 제형의 종류, 및 환자의 연령, 체중, 일반 건강 상태, 성별 및 식이, 투여 시간, 투여 경로 및 조성물의 분비율, 치료기간, 동시 사용되는 약물을 비롯한 다양한 인자에 따라 조절될 수 있다. 본 발명의 예방, 치료 또는 개선 방법에 있어서, 성인의 경우, 혼합 추출물; 양배추 추출물; 꿀; 생강즙; 및 스테비아로 이루어진 혼합물을 1일 1회 내지 수회 투여시, 0.001 g/kg 내지 10 g/kg의 용량으로 투여하는 것이 바람직하다.The term "effective amount" as used herein refers to the amount of an active ingredient or pharmaceutical composition that induces a biological or medical response in a tissue system, animal or human, which is considered by a researcher, veterinarian, doctor or other clinician, which Includes an amount that induces relief of symptoms of the disease or disorder. It is apparent to those skilled in the art that the effective amount and the number of administrations for the active ingredient of the present invention will vary depending on the desired effect. Therefore, the optimal dosage to be administered can be easily determined by those skilled in the art, and the type of disease, the severity of the disease, the content of active ingredients and other ingredients contained in the composition, the type of formulation, and the age, weight, and general health of the patient. It can be adjusted according to various factors including condition, sex and diet, time of administration, route of administration and rate of secretion of the composition, duration of treatment, and drugs used concurrently. In the prevention, treatment or improvement method of the present invention, in the case of an adult, a mixed extract; Cabbage extract; honey; Ginger juice; And when the mixture consisting of stevia is administered once to several times a day, it is preferable to administer in a dose of 0.001 g/kg to 10 g/kg.
본 발명의 치료방법에서 혼합 추출물; 양배추 추출물; 꿀; 생강즙; 및 스테비아로 이루어진 혼합물을 유효성분으로 포함하는 조성물은 경구, 직장, 정맥내, 동맥내, 복강내, 근육내, 흉골내, 경피, 국소, 안구내 또는 피내 경로를 통해 통상적인 방식으로 투여할 수 있다.
Mixed extract in the treatment method of the present invention; Cabbage extract; honey; Ginger juice; And a composition comprising a mixture consisting of stevia as an active ingredient can be administered in a conventional manner through oral, rectal, intravenous, intraarterial, intraperitoneal, intramuscular, intrasternal, transdermal, topical, intraocular or intradermal routes. have.
이하, 본 발명의 이해를 돕기 위하여 바람직한 실시예를 제시하나, 하기 실시예는 본 발명을 예시하는 것일 뿐 본 발명의 범주 및 기술사상 범위 내에서 다양한 변경 및 수정이 가능함은 당업자에게 있어서 명백한 것이며, 이러한 변형 및 수정이 첨부된 특허청구범위에 속하는 것도 당연한 것이다.Hereinafter, a preferred embodiment is presented to aid in the understanding of the present invention, but it is obvious to those skilled in the art that various changes and modifications are possible within the scope of the present invention and the scope of the technical idea, but the following examples are only illustrative of the present invention, It is natural that such modifications and modifications fall within the scope of the appended claims.
실시예 1. Example 1.
엉겅퀴의 제조Manufacture of thistle
엉겅퀴의 꽃 1 중량부, 줄기와 잎의 혼합물(줄기:잎=1:2 중량비) 18.6 중량부 및 물 45 중량부를 혼합하여 95 ℃에서 24시간 동안 중탕 추출하여 A 추출물을 수득한 후 엉겅퀴 뿌리 0.4 중량부 및 물 45 중량부를 95 ℃에서 24시간 동안 중탕 추출하여 B 추출물을 수득한 다음 각각 동결건조시켜 A 분말과 B 분말을 제조하여 혼합함으로써 엉겅퀴 혼합 추출물 분말을 제조하였다.Thistle flower 1 part by weight, a mixture of stem and leaf (stem: leaf = 1:2 weight ratio) 18.6 parts by weight and 45 parts by weight of water were mixed and extracted with water at 95° C. for 24 hours to obtain extract A, and then thistle root 0.4 Part by weight and 45 parts by weight of water were extracted in a bath at 95° C. for 24 hours to obtain extract B, and then freeze-dried to prepare and mix powder A and powder B to prepare a mixed thistle extract powder.
양배추 추출물의 제조Preparation of cabbage extract
세척한 양배추 10 중량부와 물 40 중량부를 혼합한 후 95 ℃에서 8시간 동안 중탕 추출하여 양배추 추출물을 제조하였다.After mixing 10 parts by weight of washed cabbage and 40 parts by weight of water, the cabbage extract was prepared by extracting in a bath for 8 hours at 95°C.
혼합물의 제조Preparation of mixture
상기 제조된 엉겅퀴와 민들레를 1 : 0.42의 중량비로 혼합한 후 상기 혼합물과 물을 1 : 9의 중량비로 혼합하여 90 ℃에서 48시간 동안 추출함으로써 혼합 추출물을 제조하였다. 상기 혼합 추출물 100 중량부에 상기 양배추 추출물 11.2 중량부 및 생강즙 0.75 중량부를 첨가하여 상온에서 10분 동안 혼합한 다음 꿀 2.5 중량부 및 스테비아 0.25 중량부로 첨가하여 상온에서 10분 동안 더 혼합하고 한천 0.25 중량부를 첨가하여 5분 더 혼합함으로써 혼합 추출물, 양배추 추출물, 꿀, 생강즙 및 스테비아로 이루어진 혼합물을 수득하였다.
After mixing the prepared thistle and dandelion at a weight ratio of 1:0.42, the mixture and water were mixed at a weight ratio of 1:9 and extracted for 48 hours at 90°C to prepare a mixed extract. 11.2 parts by weight of the cabbage extract and 0.75 parts by weight of ginger juice were added to 100 parts by weight of the mixed extract, mixed for 10 minutes at room temperature, and then 2.5 parts by weight of honey and 0.25 parts by weight of stevia were added, further mixed for 10 minutes at room temperature, and 0.25 parts by weight of agar By adding parts and mixing for another 5 minutes, a mixture consisting of a mixed extract, cabbage extract, honey, ginger juice, and stevia was obtained.
비교예 1. 혼합 추출물만 이용Comparative Example 1. Using only mixed extracts
상기 실시예 1과 동일하게 실시하되, 양배추 추출물, 꿀, 생강즙 및 스테비아을 사용하지 않고 엉겅퀴 및 민들레로 이루어진 혼합 추출물만 이용하였다.
It was carried out in the same manner as in Example 1, except that cabbage extract, honey, ginger juice, and stevia were not used, and only a mixed extract consisting of thistle and dandelion was used.
비교예 2. 양배추 추출물 생략Comparative Example 2. Omission of cabbage extract
상기 실시예 1과 동일하게 실시하되, 양배추 추출물을 사용하지 않고 혼합물을 수득하였다.
It was carried out in the same manner as in Example 1, but a mixture was obtained without using the cabbage extract.
비교예 3. 생강즙 생략Comparative Example 3. Ginger juice omitted
상기 실시예 1과 동일하게 실시하되, 생강즙을 사용하지 않고 혼합물을 수득하였다.
It was carried out in the same manner as in Example 1, but a mixture was obtained without using ginger juice.
비교예 3. 꿀 생략Comparative Example 3. Omission of honey
상기 실시예 1과 동일하게 실시하되, 꿀을 사용하지 않고 혼합물을 수득하였다.
It was carried out in the same manner as in Example 1, but a mixture was obtained without using honey.
비교예 4. 엉겅퀴 생략Comparative Example 4. Omission of thistle
상기 실시예 1과 동일하게 실시하되, 혼합 추출물을 제조 시 엉겅퀴를 사용하지 않고 혼합 추출물을 수득한 후 양배추 추출물, 꿀, 생강즙 및 스테비아를 혼합하여 혼합물을 수득하였다.
It was carried out in the same manner as in Example 1, but when preparing the mixed extract, a mixed extract was obtained without using thistle, and then cabbage extract, honey, ginger juice, and stevia were mixed to obtain a mixture.
<시험예><Test Example>
시험예 1. 헬리코박터 파이롤리 균 억제 효과Test Example 1. Inhibitory effect of Helicobacter pylori
H. pylori(KCTC5335, 한국생명공학연구원, Daejeon, Korea)에 대한 항균활성은 paper disk 법(agar diffusion method)으로 측정하였다. 시료는 10mm paper disk(ADVANTEC, Japan)에 준비된 시험용액을 50 μL씩 무균적으로 흡수시키고 건조하였다. 한천배지에서 배양된 H. pylori를 1X108 CFU(colony forming unit)이상이 되도록 멸균수에 현탁하여 균주액으로 하여, 항생제가 첨가되지 않은 한천배지에 각각 100 μL씩 균주액을 도말하고, 시험용액을 흡수시켜 건조한 paper disk를 H. pylori가 도말된 한천배지 위에 올려 부착시킨다. CO2 incubator에서 미호기성 상태로 72시간 동안 배양하고 H. pylori가 자라면서 paper disk 주변에 형성된 생육억제환(clear zone)의 크기 (size, mm)를 측정하였다.Antibacterial activity against H. pylori (KCTC5335, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Korea) was measured by the paper disk method (agar diffusion method). The sample was aseptically absorbed and dried by 50 μL of the test solution prepared on a 10 mm paper disk (ADVANTEC, Japan). H. pylori cultured on agar medium is suspended in sterilized water so that it is 1×10 8 CFU (colony forming unit) or higher to form a strain solution, and 100 μL of each strain solution is plated on agar medium to which antibiotics are not added, and the test solution A paper disk that has been absorbed and dried is placed on the agar medium smeared with H. pylori and attached. After incubation for 72 hours in a microaerobic state in a CO2 incubator, the size (size, mm) of the clear zone formed around the paper disk as H. pylori grew was measured.
위 표 1에 나타낸 바와 같이, 본 발명의 실시예 1에 따라 제조된 혼합물은 대조군 및 비교예 1 내지 5의 혼합물에 비하여 헬리코박터 파이롤리 균(KCTC5335)의 생육을 더욱 억제시키는 것을 확인하였다.
As shown in Table 1 above, it was confirmed that the mixture prepared according to Example 1 of the present invention further inhibited the growth of Helicobacter pyrroli bacteria (KCTC5335) compared to the mixture of the control and Comparative Examples 1 to 5.
하기에 본 발명의 분말을 함유하는 조성물의 제제예를 설명하나, 본 발명은 이를 한정하고자 함이 아닌 단지 구체적으로 설명하고자 함이다.Hereinafter, examples of the formulation of the composition containing the powder of the present invention will be described, but the present invention is not intended to limit this, but is intended to be described in detail.
제제예 1. 산제의 제조Formulation Example 1. Preparation of powder
실시예 1에서 얻은 혼합물 분말 500 mg500 mg of powder mixture obtained in Example 1
유당 100 mg100 mg lactose
탈크 10 mg10 mg of talc
상기의 성분들을 혼합하고 기밀포에 충진하여 산제를 제조한다.
The above ingredients are mixed and filled in an airtight cloth to prepare a powder.
제제예 2. 정제의 제조Formulation Example 2. Preparation of tablets
실시예 1에서 얻은 혼합물 분말 300 mg300 mg of powder mixture obtained in Example 1
옥수수전분 100 mg100 mg corn starch
유당 100 mg100 mg lactose
스테아린산 마그네슘 2 mg2 mg of magnesium stearate
상기의 성분들을 혼합한 후 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조한다.
After mixing the above ingredients, tablets are prepared by tableting according to a conventional tablet manufacturing method.
제제예 3. 캅셀제의 제조Formulation Example 3. Preparation of Capsule
실시예 1에서 얻은 혼합물 분말 200 mg200 mg of powder mixture obtained in Example 1
결정성 셀룰로오스 3 mg3 mg of crystalline cellulose
락토오스 14.8 mg14.8 mg lactose
마그네슘 스테아레이트 0.2 mgMagnesium stearate 0.2 mg
통상의 캡슐제 제조방법에 따라 상기의 성분을 혼합하고 젤라틴 캡슐에 충전하여 캡슐제를 제조한다.
According to a conventional capsule preparation method, the above ingredients are mixed and filled into gelatin capsules to prepare a capsule.
제제예 4. 주사제의 제조Formulation Example 4. Preparation of injection
실시예 1에서 얻은 혼합물 분말 600 mg600 mg of powder mixture obtained in Example 1
만니톨 180 mgMannitol 180 mg
주사용 멸균 증류수 2974 mg2974 mg of sterile distilled water for injection
Na2HPO4,12H2O 26 mgNa 2 HPO 4, 12H 2 O 26 mg
통상의 주사제의 제조방법에 따라 1 앰플 당 상기의 성분 함량으로 제조한다.
It is prepared in the amount of the above ingredients per ampoule according to a conventional injection preparation method.
제제예 5. 액제의 제조Formulation Example 5. Preparation of liquid formulation
실시예 1에서 얻은 혼합물 분말 4 g4 g of powder mixture obtained in Example 1
이성화당 10 g10 g of isomerized sugar
만니톨 5 g5 g of mannitol
정제수 적량Purified water appropriate amount
통상의 액제의 제조방법에 따라 정제수에 각각의 성분을 가하여 용해시키고 레몬향을 적량 가한 다음 상기의 성분을 혼합한 다음 정제수를 가하여 전체를 정제수를 가하여 전체 100g으로 조절한 후 갈색병에 충진하여 멸균시켜 액제를 제조한다.
According to the usual preparation method of liquid formulations, add and dissolve each component in purified water, add an appropriate amount of lemon scent, mix the above ingredients, add purified water and add purified water to adjust the total to 100 g, then fill in a brown bottle for sterilization. To prepare a liquid formulation.
제제예 6. 과립제의 제조Formulation Example 6. Preparation of granules
실시예 1에서 얻은 혼합물 분말 1,000 mg1,000 mg of powder mixture obtained in Example 1
비타민 혼합물 적량The right amount of vitamin mixture
비타민 A 아세테이트 70 ㎍Vitamin A acetate 70 ㎍
비타민 E 1.0 mg1.0 mg of vitamin E
비타민 B1 0.13 mgVitamin B1 0.13 mg
비타민 B2 0.15 mgVitamin B2 0.15 mg
비타민 B6 0.5 mg0.5 mg of vitamin B6
비타민 B12 0.2 ㎍Vitamin B12 0.2 ㎍
비타민 C 10 mg10 mg of vitamin C
비오틴 10 ㎍Biotin 10 ㎍
니코틴산아미드 1.7 mg1.7 mg of nicotinic acid amide
엽산 50 ㎍Folic acid 50 ㎍
판토텐산 칼슘 0.5 mg0.5 mg of calcium pantothenate
무기질 혼합물 적량Suitable amount of inorganic mixture
황산제1철 1.75 mgFerrous sulfate 1.75 mg
산화아연 0.82 mgZinc oxide 0.82 mg
탄산마그네슘 25.3 mgMagnesium carbonate 25.3 mg
제1인산칼륨 15 mgPotassium monophosphate 15 mg
제2인산칼슘 55 mgDicalcium phosphate 55 mg
구연산칼륨 90 mg90 mg of potassium citrate
탄산칼슘 100 mg100 mg of calcium carbonate
염화마그네슘 24.8 mgMagnesium chloride 24.8 mg
상기의 비타민 및 미네랄 혼합물의 조성비는 비교적 과립제에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상의 과립제 제조방법에 따라 상기의 성분을 혼합한 다음, 과립을 제조하고, 통상의 방법에 따라 건강기능식품 조성물 제조에 사용할 수 있다.
The composition ratio of the vitamin and mineral mixture is relatively suitable for granules, but it is also possible to arbitrarily modify the mixing ratio. After mixing the above ingredients according to a conventional granule preparation method, granules And, according to a conventional method, it can be used for preparing a health functional food composition.
제제예 7. 기능성 음료의 제조Formulation Example 7. Preparation of functional beverage
실시예 1에서 얻은 혼합물 분말 1,000 mg 1,000 mg of powder mixture obtained in Example 1
구연산 1,000 mg1,000 mg citric acid
올리고당 100 g100 g oligosaccharides
매실농축액 2 g2 g of plum concentrate
타우린 1 g1 g taurine
정제수를 가하여 전체 900 mL900 mL total by adding purified water
통상의 건강음료 제조방법에 따라 상기의 성분을 혼합한 다음, 약 1 시간 동안 85 ℃에서 교반 가열한 후, 만들어진 용액을 여과하여 멸균된 2 L 용기에 취득하여 밀봉 멸균한 뒤 냉장 보관한 다음 본 발명의 기능성 음료 조성물 제조에 사용한다. After mixing the above ingredients according to the normal health drink manufacturing method, stirring and heating the mixture at 85°C for about 1 hour, the resulting solution is filtered and obtained in a sterilized 2 L container, sealed and sterilized, and then stored in a refrigerator. It is used to prepare the functional beverage composition of the present invention.
상기 조성비는 비교적 기호음료에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 수요계층, 수요국가, 사용용도 등 지역적, 민족적 기호도에 따라서 그 배합비를 임의로 변형 실시하여도 무방하다.The composition ratio is a mixture of ingredients suitable for a relatively preferred beverage in a preferred embodiment, but the mixing ratio may be arbitrarily modified according to regional and ethnic preferences such as the demand class, the country of demand, and the purpose of use.
Claims (7)
(B) 상기 혼합 추출물에 양배추 추출물 및 생강즙을 첨가하여 혼합하는 단계; 및
(C) 상기 양배추 추출물 및 생강즙이 혼합된 혼합물에 꿀 및 스테비아를 첨가하여 혼합하는 단계;를 포함하는 것을 특징으로 하는 헬리코박터 파이로리균에 의해 발생하는 위질환의 예방 또는 개선용 식품 조성물의 제조방법.(A) mixing and extracting thistle and dandelion to obtain a mixed extract;
(B) adding and mixing cabbage extract and ginger juice to the mixed extract; And
(C) the step of mixing by adding honey and stevia to the mixture of the cabbage extract and ginger juice; and a method for preparing a food composition for preventing or improving gastric diseases caused by Helicobacter pylori, comprising.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190133633A KR102430399B1 (en) | 2019-10-25 | 2019-10-25 | A composition for improving, preventing and treating of gastrointestinal disease |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190133633A KR102430399B1 (en) | 2019-10-25 | 2019-10-25 | A composition for improving, preventing and treating of gastrointestinal disease |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20210050033A true KR20210050033A (en) | 2021-05-07 |
KR102430399B1 KR102430399B1 (en) | 2022-08-10 |
Family
ID=75916894
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020190133633A KR102430399B1 (en) | 2019-10-25 | 2019-10-25 | A composition for improving, preventing and treating of gastrointestinal disease |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102430399B1 (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20060010005A (en) * | 2004-07-27 | 2006-02-02 | 주식회사 알로에마임 | Functional food composition comprising the extract of taraxacum mongolicum h. mazz. having improving stomach disease |
KR20170044464A (en) * | 2015-10-15 | 2017-04-25 | 남부대학교산학협력단 | Compositions for treating, improving or preventing for diseases derived from helicobacter pylori |
KR20170047546A (en) * | 2015-10-23 | 2017-05-08 | 대한민국(농촌진흥청장) | A antibiotic composition for Helicobacter pylori containing the purified honey |
KR20180085079A (en) * | 2016-12-27 | 2018-07-26 | 대한민국(농촌진흥청장) | A composition for preventing, improving or treating alcoholic liver damage and alcoholic gastritis of the extracts from the aerial parts of Cirsium japonicum and Taraxacum coreanum |
KR101984129B1 (en) | 2017-11-23 | 2019-05-30 | 공주대학교 산학협력단 | Novel 1,2,4-Triazole Compound And Pharmaceutical Composition For Inhibiting Urease Comprising The Same |
-
2019
- 2019-10-25 KR KR1020190133633A patent/KR102430399B1/en active IP Right Grant
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20060010005A (en) * | 2004-07-27 | 2006-02-02 | 주식회사 알로에마임 | Functional food composition comprising the extract of taraxacum mongolicum h. mazz. having improving stomach disease |
KR20170044464A (en) * | 2015-10-15 | 2017-04-25 | 남부대학교산학협력단 | Compositions for treating, improving or preventing for diseases derived from helicobacter pylori |
KR20170047546A (en) * | 2015-10-23 | 2017-05-08 | 대한민국(농촌진흥청장) | A antibiotic composition for Helicobacter pylori containing the purified honey |
KR20180085079A (en) * | 2016-12-27 | 2018-07-26 | 대한민국(농촌진흥청장) | A composition for preventing, improving or treating alcoholic liver damage and alcoholic gastritis of the extracts from the aerial parts of Cirsium japonicum and Taraxacum coreanum |
KR101902932B1 (en) | 2016-12-27 | 2018-10-02 | 대한민국 | A composition for preventing, improving or treating alcoholic gastritis of the extracts from the aerial parts except flower and root of Cirsium japonicum and Taraxacum coreanum |
KR101984129B1 (en) | 2017-11-23 | 2019-05-30 | 공주대학교 산학협력단 | Novel 1,2,4-Triazole Compound And Pharmaceutical Composition For Inhibiting Urease Comprising The Same |
Non-Patent Citations (1)
Title |
---|
¿Qué pasa si sientes un dolor opresivo en el estómago? Identifica los síntomas y las causas de la acidez estomacal, y cuida tu salud con alimentos buenos para la acidez estomacal. NBN TV de Economía Nacional y Extranjera. [en línea], 2019.05.09., [2021.03.28. Búsqueda], Internet: <URL: http://www.nbntv.co.kr/news/articleView.html?idxno=351045> * |
Also Published As
Publication number | Publication date |
---|---|
KR102430399B1 (en) | 2022-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101135576B1 (en) | Compositions for prevention and improvement of cancer containing the extracts of native plants as an active ingredient | |
KR101781121B1 (en) | Compositions for preventing or treating for enteropathy comprising a fermentative product of an herbal extracts complex | |
KR20130004949A (en) | Composition for prevention or treatment of inner ear damage comprising an extract of piper longum l | |
KR102366919B1 (en) | Functional health food composition for inhibiting muscle reduction comprising a mixed extract of mulberry twig, Eucommia bark, Acanthopanax, and black bean | |
CN101711858B (en) | Medicine for treating cancer | |
JP2016532446A (en) | Enbu fermented food or beverage composition | |
KR20140017932A (en) | Composition of diabetes-improving effective constituents by fermentation products of the trifoliate orange | |
TWI734322B (en) | Kimchi for prevention or treatment of disease related to helicobacter pylori | |
KR102414431B1 (en) | A composition for improving, preventing and treating of diabetes mellitus | |
KR102229547B1 (en) | A composition for improving, preventing and treating of liver diseases comprising Milk thistle and Taraxacum platycarpum Dahlst | |
KR102210158B1 (en) | A composition for improving, preventing and treating of arthritis comprising Milk thistle and Achyranthes bidentata Blume | |
KR101910013B1 (en) | A composition for improving, preventing and treating of pain comprising herb extract | |
KR102430399B1 (en) | A composition for improving, preventing and treating of gastrointestinal disease | |
KR102133473B1 (en) | A composition as a prebiotic for improving intestinal microflora containing sweet potato vines | |
KR102185011B1 (en) | A composition for improving, preventing and treating of liver diseases comprising Milk thistle | |
KR102302045B1 (en) | A composition for improving, preventing and treating of liver diseases comprising Milk thistle and onion | |
KR102302047B1 (en) | Composition for hepatoprotective and ameliorating hangover | |
KR102185006B1 (en) | A composition for improving, preventing and treating of asthma and vascular disease | |
KR20100008220A (en) | Composition for preventing and treating colon cancer containing extract of mushroom and herb medicine | |
KR20040018569A (en) | Development of probiotic agent using salicornia herbacea | |
KR102478971B1 (en) | Composition for bowel movement promotion or diet | |
KR20110118748A (en) | Compositions for prevention and improvement of cancer containing the extracts of ligularia fischeri var. spiciformis nakai as an active ingredient | |
KR102036860B1 (en) | A composition as a prebiotic for improving intestinal microflora containing corchorous olitorius | |
KR102233672B1 (en) | A composition for improving, preventing and treating of diabetes mellitus comprising Milk thistle and Helianthus tuberosus | |
KR20170055366A (en) | A composition for preventing or treating obesity comprising taraxacum coreanum root extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
AMND | Amendment | ||
X701 | Decision to grant (after re-examination) | ||
GRNT | Written decision to grant |